Meningococcemia future or investigational therapies

Jump to navigation Jump to search

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia future or investigational therapies

CDC on Meningococcemia future or investigational therapies

Meningococcemia future or investigational therapies in the news

Blogs on Meningococcemia future or investigational therapies

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Future investigational therapies are showing promising results where 2 new vaccines were being developed against serogroup B and 3 new types of antigen have been found to be useful in making vaccines more potent.

Future Therapies

  • Two vaccines developed to prevent serogroup B vaccine are in late-stage clinical development in the United States.
  • A multicomponent serogroup B meningococcal vaccine (4CMenB), approved for use in Europe by the European Medicines Agency in January 2013, was developed by sequencing the meningococcal B genome and testing surface antigens for their ability to elicit an immunogenic response.
  • Three novel antigens identified, factor-H binding protein (fHbp), Neisserial adhesion A (NadA), and Neisseria heparin binding antigen (NHBA), were combined with OMV from the New Zealand epidemic strain NZ98/254[1].
  • The second vaccine, bivalent recombinant lipoprotein 2086 vaccine, contains two families of the same protein, fHbp, as 4CMenB. When these vaccines are licensed, vaccines to prevent all five serogroups that cause most meningococcal disease worldwide will be available for the first time.
  • Extensive research is needed to understand better how to conduct optimal implementation of noncapsular based meningococcal vaccines.
  • Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes.
  • In addition, educating adolescents and their parents about the benefits of receiving MenACWY is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving MenACWY vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States.

References

  1. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S; et al. (2012). "Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial". JAMA. 307 (6): 573–82. doi:10.1001/jama.2012.85. PMID 22318278.